A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
暂无分享,去创建一个
Alexander Diamantopoulos | S. Mariz | A. Diamantopoulos | J. Bottomley | Segundo Mariz | D. Tilden | Dominic P. Tilden | Gillies O’Bryan-Tear | Julia Bottomley | G. O'bryan-tear
[1] A. Cohen,et al. Interplay of diabetes and coronary heart disease on cardiovascular mortality , 2004, Heart.
[2] H. King,et al. Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.
[3] M. Hanefeld,et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes , 2005, Diabetologia.
[4] Ping Zhang,et al. Guidelines for computer modeling of diabetes and its complications , 2004 .
[5] Diabetes Uk,et al. JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practice , 2005 .
[6] R. Holman,et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.
[7] R. Holman,et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51) , 2001, Diabetologia.
[8] V. Bittner. Non-high-density lipoprotein cholesterol and cardiovascular disease. , 2003 .
[9] A. Bagust,et al. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. , 2005, Health economics.
[10] T. Cvetković,et al. Quality of Life in Type 2 Diabetic Patients , 2014 .
[11] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[12] B. Staels,et al. Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.
[13] Rury R Holman,et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). , 2002, Diabetes care.
[14] S. Wannamethee,et al. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease , 2004, Heart.
[15] John B. Buse,et al. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia , 2005 .
[16] M. Harris,et al. Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971–1993 , 1998, Diabetes Care.
[17] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[18] D. Matthews,et al. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[19] B. Manns,et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. , 2003, Health economics.
[20] B. Sobel,et al. Cardiovascular complications in diabetes mellitus. , 2005, Current opinion in pharmacology.
[21] D. Panagiotakos,et al. Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals. , 2005, Atherosclerosis.
[22] Alastair Gray,et al. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[23] R. Holman,et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) , 2005, Diabetologia.
[24] R Legood,et al. The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[25] S. Grundy,et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.
[26] Alfonso T. Perez,et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy , 2006, Diabetes & vascular disease research.
[27] A. Morris,et al. Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population‐based study , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[28] M. Hanefeld,et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. , 2007, Journal of the American College of Cardiology.